Purpose: Epilepsy is a common neurologic disorder requiring continued treatment during pregnancy. Treatment with antiepileptic drugs (AEDs) is needed for seizure control, but the risk of adverse events has to be minimized for both mother and foetus.
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Introduction
Pregnant women with epilepsy should continue treatment with antiepileptic drugs (AEDs), to reduce the maternal and foetal trauma caused by seizures. This presents challenges to disease management, because the physiological alterations of pregnancy impact AED pharmacokinetics [1] . The risk of adverse events must be minimized considering that it may affect both the mother and the developing foetus, during gestation, delivery, and the perinatal and postnatal stages [1] . 
Methods
The global safety database for ESL was reviewed for all notified pregnancy cases involving ESL exposure either as monotherapy or as add-on therapy. Cases reported up to October 21 st , 2017, occurring during clinical trials (CTs) and in the post-marketing surveillance (PMS) setting were assessed. EMBASE™ and MEDLINE ® were searched for literature reports on the use of ESL during pregnancy. The search string used was:
"eslicarbazepine" or "eslicarbazepine acetate" or "Zebinix" or "Exalief" or "BIA 2-093" or "SEP-0002093" or "Aptiom". Citations and/or abstracts retrieved between May 1 st ,
2009 and October 21 st , 2017 were evaluated using the following search terms:
"'pregna", "malform", "terato", "embryo", "foeto", "defect", "congen", "menstru", "fertile", "birth", "lact", "nurs" and "breast". PMS cases reported to EURAP were not included in this analysis due to data property. No ethics committee approval was needed, since this was a literature search combined with a pharmacovigilance database review. For
PMS cases, data protection measures and patient informed consent had been obtained according to the applicable legislation.
Results
Overall, 91 pregnancy notifications were identified from a total of 4849 reports (829 from CTs and 4020 from PMS) in ESL's safety database. Seventy-nine correspond to pregnancies with exposure to ESL, of which 28 and 51 cases occurred during CTs (Table S1 ) and 8-years of PMS, respectively (Figure 1) . Thirty of the pregnancies resulted in live birth without congenital anomalies, while in 25 cases the outcome of pregnancy is ongoing. From the 18 abortions reported, eight cases corresponded to induced abortions and ten to spontaneous events (Table S1 and S2). Two cases of abortion occurred at 2 nd trimester: one CT case of a pregnant woman medicated also with oxcarbazepine (OXC) which experienced induced abortion (high-risk pregnancy, no foetal abnormalities seen in ultrasound); and one PMS case of a woman with history of antiphospholipid syndrome. For both cases, the causal relationship to ESL was assessed as not related. Five congenital anomalies were identified, 1 case from CT and 4 from PMS ( Table 1) . Table S3 summarize the outcomes and the timing of ESL exposure.
The literature search did not provide additional information on the use of ESL during pregnancy.
Discussion and conclusions
Treatment of women with epilepsy who are pregnant or wish to become pregnant can be demanding, due to the fine balance between minimizing maternal and foetal health risks. A robust knowledge of the effects of AED exposure during pregnancy is essential
to design a suitable treatment strategy and inform women wishing to conceive while on AED therapy [2] . pregnancies were ongoing at the time of report and for 3 cases the outcome is unknown. One case of maternal sudden unexpected death in epilepsy (SUDEP) was identified ( Table S1 ). It corresponds to a 28-year old patient, co-medicated with carbamazepine and topiramate, that discontinued ESL 42 days before fatal event.
Data suggest pregnant women are at an increased risk for epilepsy-related death, including SUDEP [5] . AED regimen-related factors may play a role in SUDEP, including dose reduction due to teratogenicity concerns and changes in drug clearance [1] .
From clinical trials, 8 elective abortions were reported, nevertheless with no information on foetal congenital anomalies, though, for some of these events, various clinical and personal reasons were provided ( Table S1 ). The 4 cases of spontaneous abortion occurred in CTs, two of them were assessed by Principal Investigator as not related or unlikely and the other two as possible related. Regarding to 8-years of postmarketing, in 5 PMS cases other AEDs were concomitantly administered and four of pregnant women had age ≥ 35-years-old ( Table S2 ). The pregnant patient under ESL therapy, without concomitantly AEDs, had medical history of antiphospholipid syndrome. ESL was used concomitantly to other AED in 11 of the 15 pregnancies for which an adverse outcome was reported (spontaneous abortion and/or congenital anomaly). The role of the concomitant AEDs in the pregnancies outcome should be considered, since the risk of adverse events increases with polytherapy regimens [1] .
Polytherapy regimens containing valproate, specifically, are linked to a greater risk of
congenital malformations than polytherapy without it [6] . The relationship of other polytherapy regimens with adverse pregnancy outcomes is not established, but polytherapy with the newer AEDs appears associated with a lower malformation risk [6] . A population-based cohort study found no association between AEDs during pregnancy and spontaneous abortions. Nevertheless, a harmful effect of ESL and/or other AEDs cannot be excluded [7] .
Three reports were considered to be possibly related to ESL exposure: one report of a congenital anomaly ("de novo" in chromosome 18) from a woman concomitantly exposed to lamotrigine; one report of talipes which refers to a mother with history of alcohol, tobacco and marijuana use and concomitantly given lacosamide; and one spontaneous abortion of possibly conjoined twins (unconfirmed diagnosis) in a patient concomitantly exposed to levetiracetam ( Table 1) . The other two reports of congenital anomalies were considered not related to ESL: a male baby with congenital knee dislocation, indicated by treating physicians (neurologist and traumatologist) to be caused by a bad position in utero; and one spontaneous abortion with reported cytogenetic anomaly was also considered as not related since the patient became pregnant prior to start ESL therapy ( Table 1) . From these five cases, ESL was used as monotherapy in just one case (assessed as not related).
Newer AEDs are increasingly recognized as an option for the treatment of pregnant women, because of the overall improved tolerability profile and weaker effect on enzyme induction [8] . Recently, the outcomes of 101 prospective cases of pregnant women exposed to lacosamide in monotherapy (15.8%) and as adjunctive therapy (83.2%) were reported [9] . Most reports resulted in healthy live births (75/101), 26
abortions (11 spontaneous and 15 induced) and six cases of malformation with no identifiable pattern (five in polytherapy). Pregnancy outcomes in perampanel clinical
studies were also reviewed: from 25 pregnancies, 17 resulted in abortions (12 induced and 5 spontaneous), 5 healthy live births, 1 neonate death and 2 subjects were lost to follow-up [10] . The outcome of 2 pregnancies were assessed by investigator as possibly related, the others as unrelated to study drug.
Available data of newer AEDS are insufficient in quantity and detail to conclude about their safety in pregnancy due to small sample size, nature of safety reporting and concomitant use of AEDs.
OXC, which is another AED of the dibenzazepine family, has been linked with congenital anomalies, and pregnancy and delivery complications [11] . However, evidence originates from small case series and studies, and the overall risk for adverse pregnancy outcomes is not increased with OXC [11] . Following treatment with oral OXC, plasma concentration of the active metabolite (a mixture of (R)-and (S)-licarbazepine) decreases, with potential impact on seizure control [12] .
Pharmacokinetics of ESL during pregnancy has not been investigated and no dose adjustment has been recommended.
Although no particular safety problem was identified, ESL should only be prescribed to pregnant women if the benefits over disease control justify the potential risks. For women already taking ESL that become or are planning to become pregnant, maintenance of ESL should be assessed and special attention should be given to the maintenance of polytherapy.
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